A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial
Phase 2
- Conditions
- HIV Infections
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- VIRxSYS Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00622232
- Locations
- ๐บ๐ธ
Jacobi Medical Center, New York, New York, United States
๐บ๐ธCIRCLE Medical, LLC, Norwalk, Connecticut, United States
Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
Phase 2
- Conditions
- HIV Infection
- Interventions
- Genetic: VRX496-Modified Autologous T cells
- First Posted Date
- 2005-08-18
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- VIRxSYS Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT00131560
- Locations
- ๐บ๐ธ
University of Kentucky, Lexington, Kentucky, United States
๐บ๐ธStanford AIDS Clinical Trials Unit, Palo Alto, California, United States
๐บ๐ธCIRCLE Medical, LLC, Norwalk, Connecticut, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath